Merck Sharp + Dohme Corp.

Akzo Nobel N.v.

Akco Nobel

Merck Sharp + Dohme B.v.

Jocominus Antonius Maria Zwinkels

Pieter De Haan

Ryoichi Morita

Theodora Antonia Maria Lambregts Vd Hurk

Adrianus Cornelis Petrus Rovers

Albert Falivene Aldea

Jan-Piet Wijgergangs

The invention is a pharmaceutical tablet formulation comprising between about 12.5 mg and 100 mg losartan potassium, between about 6.25 mg and about 50 mg chlorthalidone, and sodium bicarbonate in an amount between about 1.0% and about 10.0% by weight.

Pharmaceutical formulation comprising losartan potassium and chlorthalidone

A stabilized pharmaceutical dosage unit comprising tibolone, in an amount of from 0.1% to 10% by weight of the dosage unit, and a pharmaceutically acceptable carrier. The dosage unit is contained in a humid atmosphere of 50 to 70% relative humidity until administration.

Stabilized tibolone compositions

The invention pertains to a pharmaceutical dosage unit, such as a tablet or a capsule, comprising an effective amount of tibolone (generally of from 0.1 to 10% by weight) and a starch-containing pharmaceutically acceptable carrier (also denoted as basic granulate), wherein the carrier contains of from 10 to 100% by weight of the starch. Thus a more stable tibolone formulation is obtained, allowing dry storage and lower doses of active ingredient.

Growing community of inventors

Nistelrode, Netherlands

Jocominus Antonius Maria Zwinkels